17/06/2026
The popular joint supplement glucosamine is linked to a 25% faster progression from mild cognitive impairment to Alzheimer's disease.
A groundbreaking study published in Nature Metabolism has uncovered a troubling connection between glucosamine—a widely used over-the-counter supplement for joint pain—and accelerated cognitive decline.
Researchers at the University of Florida analyzed 12 years of electronic health records and discovered that patients with mild cognitive impairment (MCI) who regularly took glucosamine were 25% more likely to progress to full-blown Alzheimer's disease than non-users.
Even more concerning, for individuals already diagnosed with dementia, the supplement was associated with a 25% increase in mortality risk. Because glucosamine easily crosses the blood-brain barrier, scientists believe it feeds into an already overactive protein 'sugar-tagging' pathway in vulnerable brains, worsening metabolic dysfunction.
Crucially, researchers emphasize that this risk appears highly specific to individuals whose brains are already undergoing neurodegeneration. In cognitively healthy adults, previous research has actually suggested that glucosamine may have a protective effect. However, with an estimated 40 million glucosamine users in the United States alone—including many seniors who deal with both joint stiffness and cognitive changes—these preliminary findings underscore the urgent need for clinical trials. Until those trials provide definitive answers, experts suggest that individuals with cognitive concerns consult their healthcare providers before continuing their daily joint supplement routine.
source: Hawkinson, T. R., Gentry, M. S., & Sun, R. (2026). Hyperglycosylation is a metabolic driver of Alzheimer's disease. Nature Metabolism.
